Cargando…

Elevated levels of circulating ITIH4 are associated with hepatocellular carcinoma with nonalcoholic fatty liver disease: from pig model to human study

BACKGROUND: Noninvasive biomarkers are urgently needed for optimal management of nonalcoholic fatty liver disease (NAFLD) for the prevention of disease progression into nonalcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC). In order to identify the biomarkers, we generated the swine...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakamura, Naohiko, Hatano, Etsuro, Iguchi, Kohta, Sato, Motohiko, Kawaguchi, Hiroaki, Ohtsu, Iwao, Sakurai, Takaki, Aizawa, Nobuhiro, Iijima, Hiroko, Nishiguchi, Shuhei, Tomono, Takuya, Okuda, Yukihiro, Wada, Seidai, Seo, Satoru, Taura, Kojiro, Uemoto, Shinji, Ikegawa, Masaya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6591942/
https://www.ncbi.nlm.nih.gov/pubmed/31238892
http://dx.doi.org/10.1186/s12885-019-5825-8
_version_ 1783429811702595584
author Nakamura, Naohiko
Hatano, Etsuro
Iguchi, Kohta
Sato, Motohiko
Kawaguchi, Hiroaki
Ohtsu, Iwao
Sakurai, Takaki
Aizawa, Nobuhiro
Iijima, Hiroko
Nishiguchi, Shuhei
Tomono, Takuya
Okuda, Yukihiro
Wada, Seidai
Seo, Satoru
Taura, Kojiro
Uemoto, Shinji
Ikegawa, Masaya
author_facet Nakamura, Naohiko
Hatano, Etsuro
Iguchi, Kohta
Sato, Motohiko
Kawaguchi, Hiroaki
Ohtsu, Iwao
Sakurai, Takaki
Aizawa, Nobuhiro
Iijima, Hiroko
Nishiguchi, Shuhei
Tomono, Takuya
Okuda, Yukihiro
Wada, Seidai
Seo, Satoru
Taura, Kojiro
Uemoto, Shinji
Ikegawa, Masaya
author_sort Nakamura, Naohiko
collection PubMed
description BACKGROUND: Noninvasive biomarkers are urgently needed for optimal management of nonalcoholic fatty liver disease (NAFLD) for the prevention of disease progression into nonalcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC). In order to identify the biomarkers, we generated the swine hepatocellular carcinoma (HCC) model associated with NAFLD and performed serum proteomics on the model. METHODS: Microminipigs were fed a high-fat diet to induce NAFLD and a normal diet as the control. To induce HCC, diethylnitrosamine was intraperitoneally administered. Biopsied liver samples were histopathologically analyzed every 12 weeks. Serum proteins were separated by blue native two-dimensional gel electrophoresis and proteins of interest were subsequently identified by MALDI-TOF MS/MS. Human serum samples were analyzed to validate the candidate protein using antibody-mediated characterization. RESULTS: In the NAFLD pigs, hepatic histology of nonalcoholic steatohepatitis (NASH) was observed at 36 weeks, and HCC developed at 60 weeks. Among serum proteins identified with MALDI-TOF MS/MS, serum inter-alpha-trypsin inhibitor heavy chain 4 (ITIH4), an acute response protein which is secreted primarily by liver, was identified as the most characteristic protein corresponding with NAFLD progression and HCC development in the NAFLD pigs. With immunoassay, serum ITIH4 levels in the NAFLD pigs were chronologically increased in comparison with those in control animal. Furthermore, immunohistochemistry showed ITIH4 expression in hepatocytes also increased in both the cancer lesions and parenchyma as NAFLD progressed. Human study is also consistent with this observation because serum ITIH4 levels were significantly higher in HCC-NAFLD patients than in the simple steatosis, NASH, and virus-related HCC patients. Of note, HCC-NAFLD patients who had higher serum ITIH4 levels exhibited poorer prognosis after hepatectomy. CONCLUSIONS: We established an HCC pig model associated with NAFLD. Serum proteomics on the swine HCC with NAFLD model implicated ITIH4 as a non-invasive biomarker reflecting NAFLD progression as well as subsequent HCC development. Most importantly, the results in the swine study have been validated in human cohort studies. Dissecting speciation of serum ITIH4 promises to have clinical utility in monitoring the disease. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-019-5825-8) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6591942
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-65919422019-07-08 Elevated levels of circulating ITIH4 are associated with hepatocellular carcinoma with nonalcoholic fatty liver disease: from pig model to human study Nakamura, Naohiko Hatano, Etsuro Iguchi, Kohta Sato, Motohiko Kawaguchi, Hiroaki Ohtsu, Iwao Sakurai, Takaki Aizawa, Nobuhiro Iijima, Hiroko Nishiguchi, Shuhei Tomono, Takuya Okuda, Yukihiro Wada, Seidai Seo, Satoru Taura, Kojiro Uemoto, Shinji Ikegawa, Masaya BMC Cancer Research Article BACKGROUND: Noninvasive biomarkers are urgently needed for optimal management of nonalcoholic fatty liver disease (NAFLD) for the prevention of disease progression into nonalcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC). In order to identify the biomarkers, we generated the swine hepatocellular carcinoma (HCC) model associated with NAFLD and performed serum proteomics on the model. METHODS: Microminipigs were fed a high-fat diet to induce NAFLD and a normal diet as the control. To induce HCC, diethylnitrosamine was intraperitoneally administered. Biopsied liver samples were histopathologically analyzed every 12 weeks. Serum proteins were separated by blue native two-dimensional gel electrophoresis and proteins of interest were subsequently identified by MALDI-TOF MS/MS. Human serum samples were analyzed to validate the candidate protein using antibody-mediated characterization. RESULTS: In the NAFLD pigs, hepatic histology of nonalcoholic steatohepatitis (NASH) was observed at 36 weeks, and HCC developed at 60 weeks. Among serum proteins identified with MALDI-TOF MS/MS, serum inter-alpha-trypsin inhibitor heavy chain 4 (ITIH4), an acute response protein which is secreted primarily by liver, was identified as the most characteristic protein corresponding with NAFLD progression and HCC development in the NAFLD pigs. With immunoassay, serum ITIH4 levels in the NAFLD pigs were chronologically increased in comparison with those in control animal. Furthermore, immunohistochemistry showed ITIH4 expression in hepatocytes also increased in both the cancer lesions and parenchyma as NAFLD progressed. Human study is also consistent with this observation because serum ITIH4 levels were significantly higher in HCC-NAFLD patients than in the simple steatosis, NASH, and virus-related HCC patients. Of note, HCC-NAFLD patients who had higher serum ITIH4 levels exhibited poorer prognosis after hepatectomy. CONCLUSIONS: We established an HCC pig model associated with NAFLD. Serum proteomics on the swine HCC with NAFLD model implicated ITIH4 as a non-invasive biomarker reflecting NAFLD progression as well as subsequent HCC development. Most importantly, the results in the swine study have been validated in human cohort studies. Dissecting speciation of serum ITIH4 promises to have clinical utility in monitoring the disease. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-019-5825-8) contains supplementary material, which is available to authorized users. BioMed Central 2019-06-25 /pmc/articles/PMC6591942/ /pubmed/31238892 http://dx.doi.org/10.1186/s12885-019-5825-8 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Nakamura, Naohiko
Hatano, Etsuro
Iguchi, Kohta
Sato, Motohiko
Kawaguchi, Hiroaki
Ohtsu, Iwao
Sakurai, Takaki
Aizawa, Nobuhiro
Iijima, Hiroko
Nishiguchi, Shuhei
Tomono, Takuya
Okuda, Yukihiro
Wada, Seidai
Seo, Satoru
Taura, Kojiro
Uemoto, Shinji
Ikegawa, Masaya
Elevated levels of circulating ITIH4 are associated with hepatocellular carcinoma with nonalcoholic fatty liver disease: from pig model to human study
title Elevated levels of circulating ITIH4 are associated with hepatocellular carcinoma with nonalcoholic fatty liver disease: from pig model to human study
title_full Elevated levels of circulating ITIH4 are associated with hepatocellular carcinoma with nonalcoholic fatty liver disease: from pig model to human study
title_fullStr Elevated levels of circulating ITIH4 are associated with hepatocellular carcinoma with nonalcoholic fatty liver disease: from pig model to human study
title_full_unstemmed Elevated levels of circulating ITIH4 are associated with hepatocellular carcinoma with nonalcoholic fatty liver disease: from pig model to human study
title_short Elevated levels of circulating ITIH4 are associated with hepatocellular carcinoma with nonalcoholic fatty liver disease: from pig model to human study
title_sort elevated levels of circulating itih4 are associated with hepatocellular carcinoma with nonalcoholic fatty liver disease: from pig model to human study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6591942/
https://www.ncbi.nlm.nih.gov/pubmed/31238892
http://dx.doi.org/10.1186/s12885-019-5825-8
work_keys_str_mv AT nakamuranaohiko elevatedlevelsofcirculatingitih4areassociatedwithhepatocellularcarcinomawithnonalcoholicfattyliverdiseasefrompigmodeltohumanstudy
AT hatanoetsuro elevatedlevelsofcirculatingitih4areassociatedwithhepatocellularcarcinomawithnonalcoholicfattyliverdiseasefrompigmodeltohumanstudy
AT iguchikohta elevatedlevelsofcirculatingitih4areassociatedwithhepatocellularcarcinomawithnonalcoholicfattyliverdiseasefrompigmodeltohumanstudy
AT satomotohiko elevatedlevelsofcirculatingitih4areassociatedwithhepatocellularcarcinomawithnonalcoholicfattyliverdiseasefrompigmodeltohumanstudy
AT kawaguchihiroaki elevatedlevelsofcirculatingitih4areassociatedwithhepatocellularcarcinomawithnonalcoholicfattyliverdiseasefrompigmodeltohumanstudy
AT ohtsuiwao elevatedlevelsofcirculatingitih4areassociatedwithhepatocellularcarcinomawithnonalcoholicfattyliverdiseasefrompigmodeltohumanstudy
AT sakuraitakaki elevatedlevelsofcirculatingitih4areassociatedwithhepatocellularcarcinomawithnonalcoholicfattyliverdiseasefrompigmodeltohumanstudy
AT aizawanobuhiro elevatedlevelsofcirculatingitih4areassociatedwithhepatocellularcarcinomawithnonalcoholicfattyliverdiseasefrompigmodeltohumanstudy
AT iijimahiroko elevatedlevelsofcirculatingitih4areassociatedwithhepatocellularcarcinomawithnonalcoholicfattyliverdiseasefrompigmodeltohumanstudy
AT nishiguchishuhei elevatedlevelsofcirculatingitih4areassociatedwithhepatocellularcarcinomawithnonalcoholicfattyliverdiseasefrompigmodeltohumanstudy
AT tomonotakuya elevatedlevelsofcirculatingitih4areassociatedwithhepatocellularcarcinomawithnonalcoholicfattyliverdiseasefrompigmodeltohumanstudy
AT okudayukihiro elevatedlevelsofcirculatingitih4areassociatedwithhepatocellularcarcinomawithnonalcoholicfattyliverdiseasefrompigmodeltohumanstudy
AT wadaseidai elevatedlevelsofcirculatingitih4areassociatedwithhepatocellularcarcinomawithnonalcoholicfattyliverdiseasefrompigmodeltohumanstudy
AT seosatoru elevatedlevelsofcirculatingitih4areassociatedwithhepatocellularcarcinomawithnonalcoholicfattyliverdiseasefrompigmodeltohumanstudy
AT taurakojiro elevatedlevelsofcirculatingitih4areassociatedwithhepatocellularcarcinomawithnonalcoholicfattyliverdiseasefrompigmodeltohumanstudy
AT uemotoshinji elevatedlevelsofcirculatingitih4areassociatedwithhepatocellularcarcinomawithnonalcoholicfattyliverdiseasefrompigmodeltohumanstudy
AT ikegawamasaya elevatedlevelsofcirculatingitih4areassociatedwithhepatocellularcarcinomawithnonalcoholicfattyliverdiseasefrompigmodeltohumanstudy